Brother Technology (002562): High performance in the first three quarters, and there is broad scope for production expansion under construction
Brother Technology (002562): Q2 performance continues to soar, transformation and growth can be expected
Brother Technology (002562) covered for the first time: the prices of vitamin K3 and calcium pantothenate rose sharply, and the continuous release of various businesses contributed to performance
Brother Technology (002562): A sharp increase in performance and the beginning of transformation
Brother Technology (002562): Performance is in line with expectations, the phenol and iodine contrast agent projects are expected to drive the company's growth
Brother Technology (002562) incident review: Benzodiol project put into operation, future growth can be expected
Brother Technology (002562): Q3 performance dropped month-on-month and fund-raising projects opened up room for growth.
Brother Technology (002562): the profitability of the industry has greatly improved and the fund-raising projects have been put into production and started to grow.
Brother Technology (002562): performance is in line with expectations and profits have improved significantly.
Brother Science and Technology (002562): fundraising products have landed vitamin subdivision leader set sail
Brother Technology (002562): rising vitamin prices, resumption of production by subsidiaries, CISA and Q1 outstanding performance
Brother Technology (002562) 2020Q1 comments: the performance is in line with the expected fixed increase plan to increase the future
Brother Science and Technology (002562): the booming performance of reproducing superimposed vitamins is expected to usher in an inflection point.
兄弟科技(002562):年报业绩符合预期 定增计划加码未来
兄弟科技(002562):盈利底部企稳 2020年拐点向上
兄弟科技(002562):维生素业务反转 矶山基地放量
兄弟科技(002562):业绩拐点显现 成长启动元年
兄弟科技(002562)深度报告:企业发展迎拐点 江西项目助成长
兄弟科技(002562):业绩回暖 2020年有望迎经营拐点
兄弟科技(002562)年报一季报点评:业绩低点已过 维生素业务迎来景气周期